GLIPR1 and hepatocellular carcinoma: Notably, in hepatocellular carcinoma, GLIPR1 activates the PI3K/PDK1/ROCK1 signaling axis, thereby enhancing EMT, cellular motility, and resistance to 5-fluorouracil [51].